Answer capsule
A public federal governance pattern shows why serious AI exceptions should identify the accountable official, the evidence considered, and the conditions for continued use.
What the source establishes
- OMB M-25-21 directs U.S. federal agencies to manage high-impact AI uses through minimum risk-management practices.
- The memorandum assigns designated agency officials authority over pilot certifications and waivers and requires a signed record when certain AI risks are accepted.
- It says agencies should discontinue a high-impact AI use when its performance is inadequate or risks cannot be sufficiently mitigated.
- M-25-21 governs federal agencies and is not a private-sector board or corporate governance rule.
Move exceptions out of project shorthand
Terms such as pilot, temporary waiver, business acceptance, and human in the loop often conceal who actually decided that an AI risk was tolerable. A CEO operating model should require a named decision owner whenever a use moves forward without a standard control, misses an evaluation threshold, or depends on an unverified mitigation. The record should identify the affected people and decisions, expected value, observed performance, unresolved risk, alternatives considered, duration, and authority of the person accepting the exposure. That turns an exception from a delivery note into an executive decision that can be governed.
The accountable team should translate this point into a named workflow, affected population, source data, human owner, approval right, exception path, retained evidence, and review date. That translation is what separates an interesting AI development from a decision that can be governed and evaluated.
Match authority to consequence
Not every deviation belongs with the CEO or board. Define tiers based on customer, employee, safety, rights, financial, operational, and reputational consequence, then assign approval authority for each tier. Business, technology, risk, legal, security, and domain specialists can supply evidence without becoming the owner of a decision they do not control. High-consequence acceptance should not be delegated to the vendor or product team whose schedule benefits from launch. The approving executive needs enough independence, standing, and information to restrict the use, impose conditions, or decline it.
The accountable team should translate this point into a named workflow, affected population, source data, human owner, approval right, exception path, retained evidence, and review date. That translation is what separates an interesting AI development from a decision that can be governed and evaluated.
Give acceptance an expiry and a stop rule
Risk acceptance is not permanent permission. Record a review date, maximum duration, required remediation, monitoring indicators, consequence limits, and events that automatically suspend or escalate the use. Performance deterioration, material model change, expansion to a new population, an incident, loss of a key control, or inability to verify an outcome may all reopen the decision. If evidence shows the system is not performing adequately or the risk cannot be sufficiently mitigated, stopping or narrowing the use should be an available operating outcome rather than an admission that the innovation program failed.
The accountable team should translate this point into a named workflow, affected population, source data, human owner, approval right, exception path, retained evidence, and review date. That translation is what separates an interesting AI development from a decision that can be governed and evaluated.
Report the pattern, not just the inventory
A board view should show where exceptions accumulate, how long they remain open, which executives repeatedly accept them, whether remediation closes on time, and what value was actually realized under the exception. Concentration can reveal an underfunded control, an unrealistic standard, a weak vendor dependency, or a business unit normalizing exposure. M-25-21 is useful as a transparent federal example of named accountability and discontinuation discipline. A private enterprise must translate that pattern through its own fiduciary duties, governance documents, risk appetite, contracts, jurisdictions, and qualified advice.
The accountable team should translate this point into a named workflow, affected population, source data, human owner, approval right, exception path, retained evidence, and review date. That translation is what separates an interesting AI development from a decision that can be governed and evaluated.
Decision test
Ask whether the source changes the decision itself, the evidence required, the implementation sequence, or only the language used to describe an existing capability. Record which claims are directly supported, which are provider statements, which require an independent test, and which remain unknown. A source-linked review should make uncertainty easier to see, not bury it inside a blended score.
Questions to take into review
- Which AI matters to strategy or risk?
- What evidence supports management's claims?
- Which decision rights change?
- What work disappears, changes, or is created?
- Where could one shared AI dependency disrupt several functions?
- Which residual risks has management accepted?
- What is the value mechanism and accountable owner?
- What competing investment is displaced?
The publication supports research and executive decision preparation. It does not provide legal, financial, accounting, employment, clinical, cybersecurity, investment, procurement, or implementation advice.